Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AML

The FLT3 inhibitor, taken during chemotherapy and continued as a single agent for up to 3 years, significantly improved survival compared with standard chemotherapy.

Related Keywords

Portugal ,Vienna ,Wien ,Austria ,Lisbon ,Lisboa ,North Carolina ,United States ,Harry Erba ,Duke Cancer Institute ,Division Of Hematologic Malignancies ,European Hematology Association ,Hematologic Malignancies ,Cellular Therapy ,Hematology Association ,Annual Meeting ,Medscape Medical ,Acute Leukemia ,Acute Myeloblastic Leukemia ,Hematology ,Chemotherapy ,Neoadjuvant ,Europe ,European ,Remission ,